Cardiff Oncology, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CRDF | BBOT | APLM | SPRINT.ST | HBP.TO | NBP | |
|---|---|---|---|---|---|---|
| Market cap | 67.60M | 184.40M | 55.38M | 370.36M | 70.27M | 117.16M |
| P/E (TTM) | — | — | — | 5.0 | — | — |
| Forward P/E | -1.6 | -0.8 | -29.2 | 2.7 | -8.4 | -0.8 |
| Price/book | 2.2 | 0.6 | -12.8 | 4.1 | 4.8 | 0.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −61.33% | −81.22% | +71.38% | +380.72% | −54.68% | −75.89% |
| Today | +0.67% | −0.86% | −8.83% | +0.57% | 0.00% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CRDF news ›Cardiff Oncology (CRDF) Projected to Release Quarterly Earnings on Thursday
Posted by Mitch Edgeman on Nov 4th, 2026 NASDAQ CRDF opened at $0.86 on Wednesday. The business has a fifty day simple moving average of $1.08 and a 200 day simple moving average of $1.43. Cardiff Oncology has a 12 month low of $0.76 and a…
Yorkshire Cancer Research–Sheffield Pioneers Funding 2027
OncoDaily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by…
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a…
Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
Cardiff Oncology Inc CRDF
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1…
Comparing Opus Genetics (NASDAQ:IRD) & Cardiff Oncology (NASDAQ:CRDF)
Posted by Danessa Lincoln on Oct 27th, 2026 Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the…
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ('Cardiff') and Nerviano Medical Science... Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement…
Cardiff Oncology to Participate in September 2026 Conferences
SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhi... Cardiff Oncology to Participate in September 2026 Conferences SAN DIEGO, Sept. 02, 2026…
Cardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Cardiff Oncology (CRDF) to Buy from Neutral with a $9 price target The company reached a settlement with Nerviano and ... Cardiff Oncology upgraded to Buy from Neutral at H.C. Wainwright H.C. Wainwright upgraded…
Cardiff scientist awarded £500,000 for cancer treatment research
A Cardiff scientist has been awarded £500,000 to investigate how treatments that use the immune system to target cancer could help more patients. Dr Bruce MacLachlan, based at Cardiff University’s School of Medicine, has received a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com4
- themarketsdaily.com3
- gurufocus.com1
- morningstar.com1
- pluang.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.